Reduced chemotherapy duration: A good idea?

Joleen Hubbard, Axel Grothey

Research output: Contribution to journalReview articlepeer-review


Over the past three decades, survival outcomes of high-risk stage II and stage III colon cancer have improved with the use of adjuvant chemotherapy. Oxaliplatin and fluoropyrimidine combination regimens, given for 6 months, are the current standard of care. However, chronic peripheral neuropathy can result as a side effect of oxaliplatin use. Investigators have questioned whether the recommended duration of adjuvant therapy is necessary. This review discusses the history of adjuvant therapy for colon cancer and provides a rationale for an ongoing clinical trial collaboration addressing the optimal duration of adjuvant therapy.

Original languageEnglish (US)
Pages (from-to)241-245
Number of pages5
JournalCurrent Colorectal Cancer Reports
Issue number3
StatePublished - Sep 2011


  • 5-fluorouracil
  • Adjuvant therapy
  • Chemotherapy-induced sensory neuropathy
  • Colon cancer
  • Oxaliplatin
  • Peripheral neuropathy

ASJC Scopus subject areas

  • Hepatology
  • Oncology
  • Gastroenterology


Dive into the research topics of 'Reduced chemotherapy duration: A good idea?'. Together they form a unique fingerprint.

Cite this